Tagged with IP

Egypt Egypt’s largest pharmaceutical manufacturer by units, EIPICO, plans to diversify its production capacity by building the country’s first biological & biosimilar production plant. Not only that, the company is leading the change towards localization and local production of APIs. Founded in 1980, EIPICO is currently the number one company in…

Egypt The chairman of EIPICO – Egypt’s largest pharma company by units –, Dr Ahmed Kelani, outlines the company’s ambitious growth strategy, which includes the construction of the first biological & biosimilar production plant in Egypt. The plant is expected to commence production at the end of 2023 and would become…

Global Pharma companies no longer view digital as a “nice to have” add on, but as an integral part of their business, yet there are still quite a few hurdles to overcome. Insights from pharma industry digital transformation leaders. Industry is on a dedicated and focused journey to leverage data and…

Global Swiss pharma giant, Roche, has announced a change in leadership that will see Severin Schwan replaced by diagnostics division head, Thomas Schinecker, after a 14-year stint as CEO. Schinecker, who became a contender for the role by leading the company’s efforts in developing a COVID-19 test kit, growing sales by…

Spain After decades of investment, Catalonia has secured its healthcare and life sciences hub status, accounting for more than half of Spain’s pharma exports and with more clinical trials than any other region. The birthplace of many of the country’s pharma success stories, Catalonia boasts a strong scientific output by European…

Italy Italy, Europe’s fourth largest pharma market at a size of EUR 23.446 billion, has a highly decentralised healthcare system, with the country’s 20 regions negotiating market access for medicines individually following central regulatory approval. This creates significant complexities for the representatives of Big Pharma looking to roll out their latest…

Global The Contract Development and Manufacturing Organisation (CDMO) industry has boomed in recent years, with Big Pharma increasingly focusing on its core business of R&D and outsourcing other elements of the supply chain, including manufacturing, to third-party CDMOs. Additionally, the global proliferation of biotechs – most of which lack the in-house…

Global French mid-cap Ipsen has signed an agreement to acquire US-based oncology specialist Epizyme, with its lymphoma drug, Tazverik, for USD 247 million to bolster its growing oncology presence. Ipsen recently announced that the deal with Epizyme’s will focus on Tazverik (tazemetostat), a first-in-class EZH2a inhibitor approved in the U.S. in…

Spain Spain is playing an important role in the production of COVID-19 vaccines with four Spanish companies involved in vaccine manufacturing projects, three of them doing fill and finish and one with an original vaccine candidate. Unfortunately, Spain’s vaccine manufacturers have faced quality control issues resulting in major recalls.   “The…

Global At the recent Global Biopharma press briefing on COVID-19, held by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), industry leaders took on the issue of vaccine inequity, challenging the view that intellectual property waivers could be the answer. 13.7 billion doses of vaccines have been delivered and 11…

Italy Ipsen’s Stephane Brocker discusses a transformational period for the iconic French mid-cap in recent years, how this has played out in Italy, and emergent trends – such as hybrid digital/in-person physician interactions – that have emerged from the COVID-19 pandemic period. Brocker also touches on Italy’s relevance to the global…

Spain HIPRA is a world-leading animal health company that has launched a record 22 animal vaccines in the last 10 years. During the COVID-19 pandemic, the European company decided to jump into human health with its own vaccine candidate, currently in phase III trials. Carles Fàbrega, managing director of HIPRA’s new…